Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2636771 in PTEN-loss Tumors (MATCH Subprotocol P)
NCT04439188Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2016
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of GSK-2636771 in malignant solid neoplasm, refractory malignant solid neoplasm, lymphoma, hematopoietic and lymphoid cell neoplasm, multiple myeloma (MM), sponsored by National Cancer Institute. Started Mar 2016; status: active, not recruiting.
02
Drugs
GSK-2636771
03
Conditions
malignant solid neoplasmrefractory malignant solid neoplasmlymphomahematopoietic and lymphoid cell neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439188.